December 1, 1990Clinical Pharmacology & Therapeutics
Combined α/β-blockade versus β1-selective blockade in essential hypertension in black and white patients
Why the study?
Does labetalol improve blood pressure reduction compared to atenolol in black and white patients with essential hypertension?
Population
292 patients with essential hypertension characterized by a standing diastolic blood pressure of 105 to 119…
Comparison
Labetalol vs Atenolol (dosage titrated from 50 to 100 mg/day)
Design
RCT, randomized
Authors
Discussion
Loading...
Member takes
Implication
Labetalol offers superior standing BP reduction versus atenolol in essential hypertension; extends support for alpha1-blockade benefit across black and white patients.
Structured PICO
Does labetalol improve blood pressure reduction compared to atenolol in black and white patients with essential hypertension?
P
Population
292 patients (152 white and 140 black) with essential hypertension characterized by a standing diastolic blood pressure of 105 to 119 mm Hg (inclusive).
I
Intervention
Labetalol (dosage titrated from 200 to 1600 mg/day)
C
Comparator
Atenolol (dosage titrated from 50 to 100 mg/day)
O
Outcome
Achievement of a standing diastolic blood pressure of 90 mm Hg or less or a fall of 15 mm Hg in diastolic pressure from baseline value at the end of the placebo run in periodsurrogate
Labetalol provides greater reduction in standing blood pressure compared to atenolol in both black and white patients with essential hypertension, demonstrating the added benefit of alpha 1-blockade.
Cite This Study
Townsend et al. (1990) studied this question.